BioSpace News Archive

Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS) today announced that it appointed Alpna Seth, Ph.D., to its Board of Directors, effective May 1, 2023.

Praxis Precision Medicines, Inc. (NASDAQ: PRAX) today announced that it will deliver presentations on its clinical stage programs at the upcoming American Academy of Neurology (AAN) 2023 Annual Meeting, held April 22-27, 2023 in Boston, Massachusetts.

Daré Bioscience, Inc., a leader in women’s health innovation, announced that the company’s Chief Scientific Officer, David Friend, Ph.D., will be presenting in the Keynote Forum of the Global Pharma & Drug Delivery Summit 2023 to be held April 24-26, 2023 in Frankfurt, Germany.

Oncotelic Therapeutics, Inc. (“Oncotelic”, “We” or the “Company”) (OTCQB:OTLC) announced today a strategic partnership with Vectara, a company specializing in innovative Natural Language Understanding (NLU) technologies, to accelerate the development of novel therapies for the treatment of cancer, infectious disease, and aging.

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) a global leader in genomics-based tests in health, wellness and serious disease is pleased to announce the publication of a research paper in “The Prostate” validating the utilisation of geneType Prostate Cancer Risk Assessment Test in the identification of men who are at increased risk of this serious disease.

ViaLase, Inc today announced that it will present new scientific research during the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting to be held April 23-27, 2023 in New Orleans, Louisiana.

AtriCure, Inc. today announced that the company will be hosting an investor education webcast in conjunction with Canaccord Genuity, focusing on Cryo Nerve Block Therapy.

Visus Therapeutics Announces New Scientific Data to Be Presented During the 2023 ARVO Annual Meeting.

Direct Biologics Reports Compelling Data as ExoFlo ™ Expanded Access Program in Hospitalized COVID-19 Patients with Moderate-to-Severe ARDS Surpasses 100 Subjects.

MoonLake Immunotherapeutics AG will host today its Capital Markets Day for investors and analysts in New York and virtually.